Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and In Vivo Activity

Fabio A Facchini, Alberto Minotti, Andrea Luraghi, Alessio Romerio, Nicole Gotri, Alejandra Matamoros-Recio, Andrea Iannucci, Charys Palmer, Guanbo Wang, Rebecca Ingram, Sonsoles Martin-Santamaria, Grisha Pirianov, Marco De Andrea, Miguel A Valvano, Francesco Peri

Research output: Contribution to journalArticlepeer-review

33 Downloads (Pure)


Modern adjuvants for vaccine formulations are immunostimulating agents whose action is based on the activation of pattern recognition receptors (PRRs) by well-defined ligands to boost innate and adaptive immune responses. Monophosphoryl lipid A (MPLA), a detoxified analogue of lipid A, is a clinically approved adjuvant that stimulates toll-like receptor 4 (TLR4). The synthesis of MPLA poses manufacturing and quality assessment challenges. Bridging this gap, we report here the development and preclinical testing of chemically simplified TLR4 agonists that could sustainably be produced in high purity and on a large scale. Underpinned by computational and biological experiments, we show that synthetic monosaccharide-based molecules (FP compounds) bind to the TLR4/MD-2 dimer with submicromolar affinities stabilizing the active receptor conformation. This results in the activation of MyD88- and TRIF-dependent TLR4 signaling and the NLRP3 inflammasome. FP compounds lack in vivo toxicity and exhibit adjuvant activity by stimulating antibody responses with a potency comparable to MPLA.

Original languageEnglish
JournalJournal of Medicinal Chemistry
Early online date12 Aug 2021
Publication statusEarly online date - 12 Aug 2021


Dive into the research topics of 'Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and In Vivo Activity'. Together they form a unique fingerprint.

Cite this